Cyclacel Pharmaceuticals, Inc. (CYCC)
USD 0.25
(2.74%)
USD 0.25
(2.74%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2023 | 389 Thousand USD | 1315.63% |
| 2022 | -32 Thousand USD | 25.58% |
| 2021 | -43 Thousand USD | -115.0% |
| 2020 | -20 Thousand USD | 0.0% |
| 2019 | -20 Thousand USD | 99.52% |
| 2018 | -4.17 Million USD | -12953.13% |
| 2017 | -32 Thousand USD | 99.63% |
| 2016 | -8.63 Million USD | 17.28% |
| 2015 | -10.43 Million USD | 36.9% |
| 2014 | -16.54 Million USD | -62.3% |
| 2013 | -10.19 Million USD | -56.26% |
| 2012 | -6.52 Million USD | -2024.19% |
| 2011 | 339 Thousand USD | 26.49% |
| 2010 | 268 Thousand USD | -26.78% |
| 2009 | 366 Thousand USD | -18.3% |
| 2008 | 448 Thousand USD | 102.3% |
| 2007 | -19.44 Million USD | 6.62% |
| 2006 | -20.81 Million USD | -2660.64% |
| 2005 | 813 Thousand USD | 1211.29% |
| 2004 | 62 Thousand USD | -63.53% |
| 2003 | 170 Thousand USD | 0.0% |
| 2002 | - USD | -100.0% |
| 2001 | 30 Thousand USD | -69.39% |
| 2000 | 98 Thousand USD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q2 | 2000.00 USD | -92.59% |
| 2024 Q1 | 27 Thousand USD | 17.39% |
| 2023 FY | 389 Thousand USD | 1315.63% |
| 2023 Q1 | -8000.00 USD | 0.0% |
| 2023 Q2 | 373.00 USD | 104.66% |
| 2023 Q3 | 9000.00 USD | 2312.87% |
| 2023 Q4 | 23 Thousand USD | 155.56% |
| 2022 Q1 | -9000.00 USD | -28.57% |
| 2022 FY | -32 Thousand USD | 25.58% |
| 2022 Q3 | -7000.00 USD | 12.5% |
| 2022 Q2 | -8000.00 USD | 11.11% |
| 2022 Q4 | -8000.00 USD | -14.29% |
| 2021 Q1 | -9000.00 USD | 99.73% |
| 2021 Q3 | -10 Thousand USD | 41.18% |
| 2021 Q4 | -7000.00 USD | 30.0% |
| 2021 Q2 | -17 Thousand USD | -88.89% |
| 2021 FY | -43 Thousand USD | -115.0% |
| 2020 Q4 | -3.34 Million USD | -211.07% |
| 2020 Q1 | -1.1 Million USD | 22.71% |
| 2020 Q3 | -1.07 Million USD | 7.57% |
| 2020 Q2 | -1.16 Million USD | -5.15% |
| 2020 FY | -20 Thousand USD | 0.0% |
| 2019 FY | -20 Thousand USD | 99.52% |
| 2019 Q3 | -1.06 Million USD | 7.81% |
| 2019 Q1 | -1.01 Million USD | -2.02% |
| 2019 Q2 | -1.15 Million USD | -13.93% |
| 2019 Q4 | -1.43 Million USD | -34.62% |
| 2018 Q3 | -1.2 Million USD | -1.95% |
| 2018 FY | -4.17 Million USD | -12953.13% |
| 2018 Q4 | -992 Thousand USD | 17.68% |
| 2018 Q1 | -798 Thousand USD | -6.97% |
| 2018 Q2 | -1.18 Million USD | -48.12% |
| 2017 Q1 | -1.31 Million USD | 20.73% |
| 2017 FY | -32 Thousand USD | 99.63% |
| 2017 Q4 | -746 Thousand USD | 22.13% |
| 2017 Q3 | -958 Thousand USD | 21.6% |
| 2017 Q2 | -1.22 Million USD | 6.86% |
| 2016 Q1 | -2.36 Million USD | -10.69% |
| 2016 Q2 | -2.41 Million USD | -2.33% |
| 2016 Q3 | -2.2 Million USD | 8.74% |
| 2016 Q4 | -1.65 Million USD | 24.91% |
| 2016 FY | -8.63 Million USD | 17.28% |
| 2015 FY | -10.43 Million USD | 36.9% |
| 2015 Q1 | -3.83 Million USD | 8.13% |
| 2015 Q2 | -2.28 Million USD | 40.37% |
| 2015 Q3 | -2.18 Million USD | 4.16% |
| 2015 Q4 | -2.13 Million USD | 2.6% |
| 2014 Q4 | -4.16 Million USD | 1.6% |
| 2014 Q3 | -4.23 Million USD | -1.15% |
| 2014 Q2 | -4.18 Million USD | -6.1% |
| 2014 Q1 | -3.94 Million USD | -80.11% |
| 2014 FY | -16.54 Million USD | -62.3% |
| 2013 Q2 | -2.36 Million USD | -73.03% |
| 2013 FY | -10.19 Million USD | -56.26% |
| 2013 Q4 | -2.19 Million USD | 48.62% |
| 2013 Q3 | -4.26 Million USD | -80.23% |
| 2013 Q1 | -1.36 Million USD | -668.54% |
| 2012 Q4 | -178 Thousand USD | 88.09% |
| 2012 Q1 | 67 Thousand USD | -23.86% |
| 2012 Q2 | 57 Thousand USD | -14.93% |
| 2012 Q3 | -1.49 Million USD | -2721.05% |
| 2012 FY | -6.52 Million USD | -2024.19% |
| 2011 Q4 | 88 Thousand USD | 27.54% |
| 2011 FY | 339 Thousand USD | 26.49% |
| 2011 Q3 | 69 Thousand USD | -28.13% |
| 2011 Q2 | 96 Thousand USD | 11.63% |
| 2011 Q1 | 86 Thousand USD | 186.67% |
| 2010 Q2 | 27 Thousand USD | -79.07% |
| 2010 Q3 | 83 Thousand USD | 207.41% |
| 2010 FY | 268 Thousand USD | -26.78% |
| 2010 Q1 | 129 Thousand USD | 13.16% |
| 2010 Q4 | 30 Thousand USD | -63.86% |
| 2009 Q1 | 112 Thousand USD | -18.25% |
| 2009 Q3 | 67 Thousand USD | -9.46% |
| 2009 Q2 | 74 Thousand USD | -33.93% |
| 2009 Q4 | 114 Thousand USD | 70.15% |
| 2009 FY | 366 Thousand USD | -18.3% |
| 2008 Q2 | 81 Thousand USD | 0.0% |
| 2008 FY | 448 Thousand USD | 102.3% |
| 2008 Q3 | 149 Thousand USD | 83.95% |
| 2008 Q4 | 137 Thousand USD | -8.05% |
| 2008 Q1 | 81 Thousand USD | 575.0% |
| 2007 Q3 | 33 Thousand USD | 6.45% |
| 2007 Q1 | 52 Thousand USD | -55.56% |
| 2007 Q2 | 31 Thousand USD | -40.38% |
| 2007 FY | -19.44 Million USD | 6.62% |
| 2007 Q4 | 12 Thousand USD | -63.64% |
| 2006 Q1 | 151 Thousand USD | -80.49% |
| 2006 Q4 | 117 Thousand USD | 40.96% |
| 2006 Q3 | 83 Thousand USD | 130.56% |
| 2006 Q2 | 36 Thousand USD | -76.16% |
| 2006 FY | -20.81 Million USD | -2660.64% |
| 2005 Q3 | 11 Thousand USD | -8.33% |
| 2005 FY | 813 Thousand USD | 1211.29% |
| 2005 Q4 | 774 Thousand USD | 6936.36% |
| 2005 Q1 | 16 Thousand USD | 23.08% |
| 2005 Q2 | 12 Thousand USD | -25.0% |
| 2004 FY | 62 Thousand USD | -63.53% |
| 2004 Q4 | 13 Thousand USD | 0.0% |
| 2004 Q3 | 13 Thousand USD | -45.83% |
| 2004 Q1 | 12 Thousand USD | -52.0% |
| 2004 Q2 | 24 Thousand USD | 100.0% |
| 2003 FY | 170 Thousand USD | 0.0% |
| 2003 Q2 | 59 Thousand USD | 353.85% |
| 2003 Q1 | 13 Thousand USD | 0.0% |
| 2003 Q4 | 25 Thousand USD | -65.75% |
| 2003 Q3 | 73 Thousand USD | 23.73% |
| 2002 FY | - USD | -100.0% |
| 2001 FY | 30 Thousand USD | -69.39% |
| 2000 FY | 98 Thousand USD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| Absci Corporation | -41.84 Million USD | 100.93% |
| Adaptive Biotechnologies Corporation | 94.72 Million USD | 99.589% |
| Alnylam Pharmaceuticals, Inc. | 1.51 Billion USD | 99.974% |
| Alzamend Neuro, Inc. | -50.74 Thousand USD | 866.654% |
| Apollomics, Inc. | 127 Thousand USD | -206.299% |
| 180 Life Sciences Corp. | -105.67 Thousand USD | 468.11% |
| Atossa Therapeutics, Inc. | -23 Thousand USD | 1791.304% |
| Bicycle Therapeutics plc | -129.52 Million USD | 100.3% |
| Barinthus Biotherapeutics plc | 802 Thousand USD | 51.496% |
| BioXcel Therapeutics, Inc. | 120 Thousand USD | -224.167% |
| CASI Pharmaceuticals, Inc. | 20.05 Million USD | 98.06% |
| Chimerix, Inc. | 324 Thousand USD | -20.062% |
| CRISPR Therapeutics AG | 240.95 Million USD | 99.839% |
| Contineum Therapeutics, Inc. Class A Common Stock | 49.8 Million USD | 99.219% |
| EyePoint Pharmaceuticals, Inc. | 41.38 Million USD | 99.06% |
| Fortress Biotech, Inc. | 57.85 Million USD | 99.328% |
| Fortress Biotech, Inc. | 57.85 Million USD | 99.328% |
| Gritstone bio, Inc. | -6.26 Million USD | 106.214% |
| Allakos Inc. | -6.14 Million USD | 106.334% |
| Boundless Bio, Inc. Common Stock | -957 Thousand USD | 140.648% |
| Cara Therapeutics, Inc. | 14.79 Million USD | 97.371% |
| Cytokinetics, Incorporated | -322.59 Million USD | 100.121% |
| enGene Holdings Inc. Common Stock | -175 Thousand USD | 322.286% |
| Innoviva, Inc. | 261.06 Million USD | 99.851% |
| Hoth Therapeutics, Inc. | - USD | -Infinity% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 3509.888% |
| RAPT Therapeutics, Inc. | -3.55 Million USD | 110.955% |
| Salarius Pharmaceuticals, Inc. | -10.05 Thousand USD | 3970.262% |
| Terns Pharmaceuticals, Inc. | -881 Thousand USD | 144.154% |
| Vigil Neuroscience, Inc. | -399 Thousand USD | 197.494% |
| ImmuCell Corporation | 4.39 Million USD | 91.152% |
| IDEAYA Biosciences, Inc. | -106.12 Million USD | 100.367% |
| Incyte Corporation | 3.44 Billion USD | 99.989% |
| Inovio Pharmaceuticals, Inc. | -2.67 Million USD | 114.561% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | -99.786% |
| Mustang Bio, Inc. | -2.22 Million USD | 117.483% |
| MiMedx Group, Inc. | 266.84 Million USD | 99.854% |
| MEI Pharma, Inc. | 49.32 Million USD | 99.211% |
| MacroGenics, Inc. | 50.52 Million USD | 99.23% |
| Monopar Therapeutics Inc. | - USD | -Infinity% |
| Mereo BioPharma Group plc | 7.42 Million USD | 94.762% |
| Marker Therapeutics, Inc. | -7.1 Million USD | 105.475% |
| Marinus Pharmaceuticals, Inc. | 29.05 Million USD | 98.661% |
| Maravai LifeSciences Holdings, Inc. | 140.2 Million USD | 99.723% |
| Minerva Neurosciences, Inc. | -30.98 Thousand USD | 1355.568% |
| NeuroBo Pharmaceuticals, Inc. | - USD | -Infinity% |
| NeuroSense Therapeutics Ltd. | -97 Thousand USD | 501.031% |
| NextCure, Inc. | -3.68 Million USD | 110.559% |
| Orchestra BioMed Holdings, Inc. | 2.57 Million USD | 84.887% |
| Ocuphire Pharma, Inc. | 19.04 Million USD | 97.957% |
| Onconetix, Inc. | -1.12 Million USD | 134.511% |
| Oncternal Therapeutics, Inc. | -28.96 Million USD | 101.343% |
| Opthea Limited | 21.72 Thousand USD | -1690.976% |
| Ovid Therapeutics Inc. | -1.2 Million USD | 132.285% |
| Psyence Biomedical Ltd. | -240.00 USD | 162183.333% |
| PDS Biotechnology Corporation | -57.32 Thousand USD | 778.575% |
| Precigen, Inc. | 106 Thousand USD | -266.981% |
| Pieris Pharmaceuticals, Inc. | 1 Million USD | 61.447% |
| Prime Medicine, Inc. | -147.9 Million USD | 100.263% |
| PureTech Health plc | -1.6 Million USD | 124.267% |
| Rocket Pharmaceuticals, Inc. | -7.09 Million USD | 105.48% |
| Regeneron Pharmaceuticals, Inc. | 11.3 Billion USD | 99.997% |
| Replimune Group, Inc. | -2.65 Million USD | 114.652% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 1652.956% |
| Rigel Pharmaceuticals, Inc. | 109.77 Million USD | 99.646% |
| TransCode Therapeutics, Inc. | -516.74 Thousand USD | 175.279% |
| Revolution Medicines, Inc. Warrant | -399.66 Million USD | 100.097% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Sesen Bio, Inc. | 40 Million USD | 99.028% |
| Sangamo Therapeutics, Inc. | -45.32 Million USD | 100.858% |
| Solid Biosciences Inc. | -76.56 Million USD | 100.508% |
| Syndax Pharmaceuticals, Inc. | -12 Thousand USD | 3341.667% |
| SciSparc Ltd. | 2.19 Million USD | 82.286% |
| Sutro Biopharma, Inc. | -26.69 Million USD | 101.457% |
| TG Therapeutics, Inc. | 219.1 Million USD | 99.822% |
| Tonix Pharmaceuticals Holding Corp. | 3.02 Million USD | 87.149% |
| Titan Pharmaceuticals, Inc. | -1.72 Million USD | 122.499% |
| Travere Therapeutics, Inc. | 133.78 Million USD | 99.709% |
| UroGen Pharma Ltd. | 73.35 Million USD | 99.47% |
| Verrica Pharmaceuticals Inc. | 4.37 Million USD | 91.115% |
| XOMA Corporation | 3.86 Million USD | 89.925% |
| Zentalis Pharmaceuticals, Inc. | -1.38 Million USD | 128.006% |
| AbCellera Biologics Inc. | 38.02 Million USD | 98.977% |
| Longboard Pharmaceuticals, Inc. | -5000.00 USD | 7880.0% |
| Cassava Sciences, Inc. | -89.42 Million USD | 100.435% |
| Corbus Pharmaceuticals Holdings, Inc. | -31.16 Million USD | 101.248% |
| Precision BioSciences, Inc. | 40.47 Million USD | 99.039% |
| Dyadic International, Inc. | 922.95 Thousand USD | 57.853% |
| Intensity Therapeutics, Inc. | -147 Thousand USD | 364.626% |
| Eton Pharmaceuticals, Inc. | 21.06 Million USD | 98.153% |
| VYNE Therapeutics Inc. | 424 Thousand USD | 8.255% |
| Tenaya Therapeutics, Inc. | -8.68 Million USD | 104.478% |
| IGM Biosciences, Inc. | -211.66 Million USD | 100.184% |
| X4 Pharmaceuticals, Inc. | -1.99 Million USD | 119.489% |
| Acelyrin, Inc. | -115 Thousand USD | 438.261% |
| Abeona Therapeutics Inc. | 2.43 Million USD | 84.025% |
| Ligand Pharmaceuticals Incorporated | 119.75 Million USD | 99.675% |
| Inhibikase Therapeutics, Inc. | -13.35 Million USD | 102.912% |
| Arcturus Therapeutics Holdings Inc. | 154.79 Million USD | 99.749% |
| Syros Pharmaceuticals, Inc. | -98.21 Million USD | 100.396% |
| Senti Biosciences, Inc. | -2.68 Million USD | 114.499% |
| Mesoblast Limited | -9.81 Million USD | 103.963% |
| Kymera Therapeutics, Inc. | -110.48 Million USD | 100.352% |
| ChromaDex Corporation | 50.78 Million USD | 99.234% |
| BriaCell Therapeutics Corp. | - USD | -Infinity% |
| Akebia Therapeutics, Inc. | 120.47 Million USD | 99.677% |
| Dermata Therapeutics, Inc. | - USD | -Infinity% |
| Seer, Inc. | 7.02 Million USD | 94.464% |
| Xeris Biopharma Holdings, Inc. | 135.26 Million USD | 99.712% |
| Novavax, Inc. | 639.93 Million USD | 99.939% |
| Virpax Pharmaceuticals, Inc. | - USD | -Infinity% |
| Fate Therapeutics, Inc. | -98.16 Million USD | 100.396% |
| Checkpoint Therapeutics, Inc. | -43.46 Million USD | 100.895% |
| Lyell Immunopharma, Inc. | 130 Thousand USD | -199.231% |
| Celcuity Inc. | -142.77 Thousand USD | 372.462% |
| ContextLogic Inc. | 59 Million USD | 99.341% |
| Phathom Pharmaceuticals, Inc. | 515 Thousand USD | 24.466% |
| HOOKIPA Pharma Inc. | 16.57 Million USD | 97.653% |
| Jazz Pharmaceuticals plc | 3.39 Billion USD | 99.989% |
| Amarin Corporation plc | 165.54 Million USD | 99.765% |
| AnaptysBio, Inc. | 14.78 Million USD | 97.368% |
| Aptevo Therapeutics Inc. | -567 Thousand USD | 168.607% |
| Aptorum Group Limited | -1.11 Million USD | 134.898% |
| Cartesian Therapeutics, Inc. | 24.45 Million USD | 98.409% |
| Arrowhead Pharmaceuticals, Inc. | 240.73 Million USD | 99.838% |
| Ardelyx, Inc. | 106.66 Million USD | 99.635% |
| Celularity Inc. | 6.75 Million USD | 94.241% |
| Omeros Corporation | -69.77 Million USD | 100.557% |
| Humacyte, Inc. | -76.55 Million USD | 100.508% |
| Immunocore Holdings plc | 248.39 Million USD | 99.843% |
| IO Biotech, Inc. | -756 Thousand USD | 151.455% |
| GT Biopharma, Inc. | - USD | -Infinity% |
| Cabaletta Bio, Inc. | -1.42 Million USD | 127.279% |
| Summit Therapeutics Inc. | -2.05 Million USD | 118.976% |
| Alaunos Therapeutics, Inc. | -4.79 Million USD | 108.108% |
| Pulmatrix, Inc. | -8.22 Million USD | 104.732% |
| Intellia Therapeutics, Inc. | -398.79 Million USD | 100.098% |
| Evogene Ltd. | 1.39 Million USD | 72.194% |
| CorMedix Inc. | -205.56 Thousand USD | 289.237% |
| BioLineRx Ltd. | 1.1 Million USD | 64.892% |
| VistaGen Therapeutics, Inc. | 496 Thousand USD | 21.573% |
| Sagimet Biosciences Inc. | 2 Million USD | 80.55% |
| PTC Therapeutics, Inc. | 872.33 Million USD | 99.955% |
| scPharmaceuticals Inc. | 9.78 Million USD | 96.023% |
| Fulcrum Therapeutics, Inc. | -68.99 Million USD | 100.564% |
| Corcept Therapeutics Incorporated | 475.89 Million USD | 99.918% |
| NLS Pharmaceutics AG | -11.4 Thousand USD | 3509.888% |
| Reviva Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Akero Therapeutics, Inc. | -29 Thousand USD | 1441.379% |
| Eliem Therapeutics, Inc. | - USD | -Infinity% |
| Lisata Therapeutics, Inc. | -189 Thousand USD | 305.82% |
| Stoke Therapeutics, Inc. | 4.05 Million USD | 90.397% |
| Reneo Pharmaceuticals, Inc. | -525 Thousand USD | 174.095% |
| Outlook Therapeutics, Inc. | -44.18 Thousand USD | 980.33% |
| ProMIS Neurosciences, Inc. | -10.44 Million USD | 103.724% |
| Daré Bioscience, Inc. | 2.76 Million USD | 85.954% |
| bluebird bio, Inc. | -4.03 Million USD | 109.653% |
| BioMarin Pharmaceutical Inc. | 1.9 Billion USD | 99.98% |
| DBV Technologies S.A. | 15.72 Million USD | 97.527% |
| Avidity Biosciences, Inc. | -181.4 Million USD | 100.214% |
| Galecto, Inc. | -830 Thousand USD | 146.867% |
| Sensei Biotherapeutics, Inc. | -571 Thousand USD | 168.126% |
| Spruce Biosciences, Inc. | -39.34 Million USD | 100.989% |
| Inhibrx Biosciences, Inc. | 609 Thousand USD | 36.125% |
| GlycoMimetics, Inc. | -143.3 Thousand USD | 371.457% |
| Arcutis Biotherapeutics, Inc. | 54.61 Million USD | 99.288% |
| ADMA Biologics, Inc. | 88.21 Million USD | 99.559% |
| Clene Inc. | 533 Thousand USD | 27.017% |
| Recursion Pharmaceuticals, Inc. | 1.98 Million USD | 80.433% |
| Aptose Biosciences Inc. | -474.54 Thousand USD | 181.973% |
| ZyVersa Therapeutics, Inc. | -10.4 Thousand USD | 3840.385% |
| Soligenix, Inc. | 97.31 Thousand USD | -299.749% |
| Century Therapeutics, Inc. | -10.8 Million USD | 103.599% |
| Kura Oncology, Inc. | -849 Thousand USD | 145.819% |
| Surrozen, Inc. | -27.23 Million USD | 101.429% |
| TScan Therapeutics, Inc. | -67.1 Million USD | 100.58% |
| Ocean Biomedical, Inc. | - USD | -Infinity% |
| CytomX Therapeutics, Inc. | 99.03 Million USD | 99.607% |
| Autolus Therapeutics plc | -4.86 Million USD | 107.993% |
| Mineralys Therapeutics, Inc. | - USD | -Infinity% |
| Eterna Therapeutics Inc. | -168 Thousand USD | 331.548% |
| Caribou Biosciences, Inc. | -77.59 Million USD | 100.501% |
| GRI Bio, Inc. | 10.84 Million USD | 96.412% |
| Xenetic Biosciences, Inc. | 2.53 Million USD | 84.685% |
| Janux Therapeutics, Inc. | -46.83 Million USD | 100.831% |
| INmune Bio, Inc. | 155 Thousand USD | -150.968% |
| Heron Therapeutics, Inc. | 61.93 Million USD | 99.372% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 125.825% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 159.989% |
| Tenax Therapeutics, Inc. | -7570.00 USD | 5238.705% |
| Jaguar Health, Inc. | 7.72 Million USD | 94.964% |
| Entero Therapeutics, Inc. | -29.27 Thousand USD | 1428.824% |
| Milestone Pharmaceuticals Inc. | 402 Thousand USD | 3.234% |
| Clearside Biomedical, Inc. | 7.87 Million USD | 95.058% |
| Atara Biotherapeutics, Inc. | -313 Thousand USD | 224.281% |
| Coherus BioSciences, Inc. | 94.46 Million USD | 99.588% |
| Verastem, Inc. | -62 Thousand USD | 727.419% |
| Pliant Therapeutics, Inc. | -261 Thousand USD | 249.042% |
| Histogen Inc. | 3.76 Million USD | 89.679% |
| Aprea Therapeutics, Inc. | 576.17 Thousand USD | 32.486% |
| ACADIA Pharmaceuticals Inc. | 680.7 Million USD | 99.943% |
| Surrozen, Inc. | -27.23 Million USD | 101.429% |
| Organovo Holdings, Inc. | -5.38 Million USD | 107.218% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Cadrenal Therapeutics, Inc. Common Stock | -1980.00 USD | 19746.465% |
| Centessa Pharmaceuticals plc | 6.06 Million USD | 93.588% |
| Hepion Pharmaceuticals, Inc. | -67.13 Thousand USD | 679.464% |
| BioRestorative Therapies, Inc. | 145.8 Thousand USD | -166.804% |
| Kronos Bio, Inc. | 1.37 Million USD | 71.647% |
| Turnstone Biologics Corp. | 16.5 Million USD | 97.643% |
| Synaptogenix, Inc. | -6347.00 USD | 6228.88% |
| Tiziana Life Sciences Ltd | -51 Thousand USD | 862.745% |
| Entrada Therapeutics, Inc. | 29.12 Million USD | 98.665% |
| Aurinia Pharmaceuticals Inc. | 161.36 Million USD | 99.759% |
| Exelixis, Inc. | 1.75 Billion USD | 99.978% |
| Nurix Therapeutics, Inc. | -112.16 Million USD | 100.347% |
| Apellis Pharmaceuticals, Inc. | 338.08 Million USD | 99.885% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 135.108% |
| ESSA Pharma Inc. | -118.49 Thousand USD | 428.295% |
| TNF Pharmaceuticals, Inc. | - USD | -Infinity% |
| Avid Bioservices, Inc. | 7.31 Million USD | 94.684% |
| Insmed Incorporated | 239.63 Million USD | 99.838% |
| MediWound Ltd. | 3.57 Million USD | 89.128% |
| OmniAb, Inc. | 14.66 Million USD | 97.348% |
| Alector, Inc. | -95.05 Million USD | 100.409% |
| Seres Therapeutics, Inc. | 125.62 Million USD | 99.69% |
| Zai Lab Limited | 170.9 Million USD | 99.772% |
| AlloVir, Inc. | -398 Thousand USD | 197.739% |
| Revance Therapeutics, Inc. | 81.87 Million USD | 99.525% |
| ORIC Pharmaceuticals, Inc. | -1.03 Million USD | 137.694% |
| Aura Biosciences, Inc. | -1.29 Million USD | 130.039% |
| Immunic, Inc. | -111 Thousand USD | 450.45% |
| Tarsus Pharmaceuticals, Inc. | 15.85 Million USD | 97.546% |
| Veracyte, Inc. | 248.14 Million USD | 99.843% |
| InMed Pharmaceuticals Inc. | -6.98 Billion USD | 100.006% |
| FibroGen, Inc. | 128.9 Million USD | 99.698% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| Catalyst Pharmaceuticals, Inc. | 313.67 Million USD | 99.876% |
| Adial Pharmaceuticals, Inc. | -564.00 USD | 69071.631% |
| Sonnet BioTherapeutics Holdings, Inc. | -11.66 Million USD | 103.334% |
| Amylyx Pharmaceuticals, Inc. | 355.34 Million USD | 99.891% |
| Fortrea Holdings Inc. | 424 Million USD | 99.908% |
| KalVista Pharmaceuticals, Inc. | -86.16 Million USD | 100.451% |
| XBiotech Inc. | -1.74 Million USD | 122.305% |
| Jasper Therapeutics, Inc. | -1.1 Million USD | 135.108% |
| Keros Therapeutics, Inc. | -664 Thousand USD | 158.584% |
| SELLAS Life Sciences Group, Inc. | - USD | -Infinity% |
| Lyra Therapeutics, Inc. | -46.47 Million USD | 100.837% |
| Foghorn Therapeutics Inc. | -75.53 Million USD | 100.515% |
| Agenus Inc. | 139.61 Million USD | 99.721% |
| Y-mAbs Therapeutics, Inc. | 73.4 Million USD | 99.47% |
| Theravance Biopharma, Inc. | 16.8 Million USD | 97.685% |
| Ultragenyx Pharmaceutical Inc. | 389.04 Million USD | 99.9% |
| Metagenomi, Inc. Common Stock | -49.64 Million USD | 100.784% |
| BioCryst Pharmaceuticals, Inc. | 326.75 Million USD | 99.881% |
| Gain Therapeutics, Inc. | -11.32 Million USD | 103.435% |
| C4 Therapeutics, Inc. | -96.95 Million USD | 100.401% |
| Creative Medical Technology Holdings, Inc. | 5400.00 USD | -7103.704% |
| Chemomab Therapeutics Ltd. | -66.82 Thousand USD | 682.1% |
| Lantern Pharma Inc. | -174.84 Thousand USD | 322.485% |
| Eledon Pharmaceuticals, Inc. | -374 Thousand USD | 204.011% |
| Ainos, Inc. | -253.73 Thousand USD | 253.311% |
| Pluri Inc. | 322 Thousand USD | -20.807% |
| Prothena Corporation plc | -129.2 Million USD | 100.301% |
| Adaptimmune Therapeutics plc | 50.42 Million USD | 99.229% |
| Rallybio Corporation | -150 Thousand USD | 359.333% |
| Kodiak Sciences Inc. | -25.94 Million USD | 101.499% |
| Cue Biopharma, Inc. | -32.6 Million USD | 101.193% |
| MeiraGTx Holdings plc | 287 Thousand USD | -35.54% |
| Annexon, Inc. | -3.26 Million USD | 111.907% |
| Assembly Biosciences, Inc. | -41.73 Million USD | 100.932% |
| Moderna, Inc. | 2.15 Billion USD | 99.982% |
| Cocrystal Pharma, Inc. | -15.16 Million USD | 102.564% |
| Cidara Therapeutics, Inc. | 62.38 Million USD | 99.376% |
| Blueprint Medicines Corporation | 236.58 Million USD | 99.836% |
| Immix Biopharma, Inc. | -5468.00 USD | 7214.119% |
| CalciMedica, Inc. | -58 Thousand USD | 770.69% |
| Monte Rosa Therapeutics, Inc. | -6.22 Million USD | 106.252% |
| Scholar Rock Holding Corporation | -2.84 Million USD | 113.678% |
| Wave Life Sciences Ltd. | 104.09 Million USD | 99.626% |
| Sana Biotechnology, Inc. | -30.86 Million USD | 101.26% |
| Elicio Therapeutics, Inc. | -1.17 Million USD | 133.248% |
| Adlai Nortye Ltd. American Depositary Shares | 2.77 Million USD | 85.985% |
| Nutriband Inc. | 862.1 Thousand USD | 54.878% |
| Protara Therapeutics, Inc. | -341 Thousand USD | 214.076% |
| Vor Biopharma Inc. | -3.49 Million USD | 111.14% |
| Roivant Sciences Ltd. | 109.23 Million USD | 99.644% |
| Alkermes plc | 1.37 Billion USD | 99.972% |
| ProKidney Corp. | -3.16 Million USD | 112.275% |
| Applied Therapeutics, Inc. | -43.91 Million USD | 100.886% |
| Arcellx, Inc. | 108.27 Million USD | 99.641% |
| BridgeBio Pharma, Inc. | 6.85 Million USD | 94.327% |
| Tango Therapeutics, Inc. | -78.67 Million USD | 100.494% |
| Galectin Therapeutics Inc. | -33 Thousand USD | 1278.788% |
| Atai Life Sciences N.V. | -5000.00 USD | 7880.0% |
| Renovaro Biosciences Inc. | -121.85 Thousand USD | 419.221% |
| Aerovate Therapeutics, Inc. | -96 Thousand USD | 505.208% |
| MediciNova, Inc. | 979.7 Thousand USD | 60.294% |
| Praxis Precision Medicines, Inc. | -84.31 Million USD | 100.461% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 511.401% |
| GeoVax Labs, Inc. | -20.72 Million USD | 101.877% |
| Axsome Therapeutics, Inc. | 244.53 Million USD | 99.841% |
| Biomea Fusion, Inc. | -4.2 Million USD | 109.26% |
| RenovoRx, Inc. | - USD | -Infinity% |
| Cullinan Oncology, Inc. | -310 Thousand USD | 225.484% |
| Geron Corporation | -123.5 Million USD | 100.315% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 7880.0% |
| 4D Molecular Therapeutics, Inc. | -76.37 Million USD | 100.509% |
| Dyne Therapeutics, Inc. | -2.46 Million USD | 115.807% |
| Kiniksa Pharmaceuticals, Ltd. | 213.73 Million USD | 99.818% |
| Royalty Pharma plc | 1.79 Billion USD | 99.978% |
| Ventyx Biosciences, Inc. | -941 Thousand USD | 141.339% |
| Imunon, Inc. | -720 Thousand USD | 154.027% |
| BioAtla, Inc. | -103.73 Million USD | 100.375% |
| Allogene Therapeutics, Inc. | -242.81 Million USD | 100.16% |
| Larimar Therapeutics, Inc. | -311 Thousand USD | 225.08% |
| Mersana Therapeutics, Inc. | -111.41 Million USD | 100.349% |
| Structure Therapeutics Inc. | -949.17 Thousand USD | 140.983% |
| 89bio, Inc. | -273 Thousand USD | 242.491% |
| Kezar Life Sciences, Inc. | -70.08 Million USD | 100.555% |
| aTyr Pharma, Inc. | -2.38 Million USD | 116.29% |
| Aligos Therapeutics, Inc. | 12.46 Million USD | 96.878% |
| Viridian Therapeutics, Inc. | -1 Million USD | 138.591% |
| EyeGate Pharmaceuticals, Inc. | 13.00 USD | -2992207.692% |
| Akari Therapeutics, Plc | -4000.00 USD | 9825.0% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Halozyme Therapeutics, Inc. | 636.89 Million USD | 99.939% |
| Lexicon Pharmaceuticals, Inc. | 1.11 Million USD | 65.237% |
| Liquidia Corporation | 14.6 Million USD | 97.336% |
| Entera Bio Ltd. | -56 Thousand USD | 794.643% |
| GH Research PLC | -315 Thousand USD | 223.492% |
| Vericel Corporation | 135.57 Million USD | 99.713% |
| Arbutus Biopharma Corporation | -55.55 Million USD | 100.7% |
| Xencor, Inc. | -85.26 Million USD | 100.456% |
| 60 Degrees Pharmaceuticals, Inc. | -220.97 Thousand USD | 276.036% |
| Pasithea Therapeutics Corp. | -648.45 Thousand USD | 159.989% |
| Coeptis Therapeutics Holdings, Inc. | -1 Million USD | 138.852% |
| Vaxcyte, Inc. | -75 Million USD | 100.519% |
| Xenon Pharmaceuticals Inc. | -167.51 Million USD | 100.232% |
| Vanda Pharmaceuticals Inc. | 177.84 Million USD | 99.781% |
| Lexaria Bioscience Corp. | 194.7 Thousand USD | -99.786% |
| Portage Biotech Inc. | -54 Thousand USD | 820.37% |
| Cardio Diagnostics Holdings, Inc. | -94.55 Thousand USD | 511.401% |
| Olema Pharmaceuticals, Inc. | -377 Thousand USD | 203.183% |
| OncoCyte Corporation | 413 Thousand USD | 5.811% |
| Qualigen Therapeutics, Inc. | -4495.00 USD | 8754.06% |
| Processa Pharmaceuticals, Inc. | -222.00 USD | 175325.225% |
| Purple Biotech Ltd. | -196 Thousand USD | 298.469% |
| Tempest Therapeutics, Inc. | -381 Thousand USD | 202.1% |
| Sol-Gel Technologies Ltd. | -21.98 Million USD | 101.769% |
| Rhythm Pharmaceuticals, Inc. | 68.12 Million USD | 99.429% |
| CollPlant Biotechnologies Ltd. | 8.96 Million USD | 95.662% |
| Moleculin Biotech, Inc. | -127 Thousand USD | 406.299% |
| United Therapeutics Corporation | 2.07 Billion USD | 99.981% |
| HilleVax, Inc. | -2.15 Million USD | 118.043% |
| Silo Pharma, Inc. | 66.26 Thousand USD | -487.046% |
| Telomir Pharmaceuticals, Inc. Common Stock | -3.94 Million USD | 109.868% |
| Pharming Group N.V. | 220.1 Million USD | 99.823% |
| Tharimmune, Inc. | - USD | -Infinity% |
| Genprex, Inc. | -15 Thousand USD | 2692.642% |
| Apogee Therapeutics, Inc. | - USD | -Infinity% |
| Neumora Therapeutics, Inc. Common Stock | -668 Thousand USD | 158.234% |
| Pyxis Oncology, Inc. | -2 Million USD | 119.45% |
| XTL Biopharmaceuticals Ltd. | - USD | -Infinity% |
| Virios Therapeutics, Inc. | - USD | -Infinity% |
| OKYO Pharma Limited | -7506.16 USD | 5282.41% |
| Savara Inc. | -44.26 Million USD | 100.879% |
| Windtree Therapeutics, Inc. | -82 Thousand USD | 574.39% |
| Curis, Inc. | 9.81 Million USD | 96.035% |
| Carmell Therapeutics Corporation | -124.78 Thousand USD | 411.729% |
| Achieve Life Sciences, Inc. | -228 Thousand USD | 270.614% |
| BeiGene, Ltd. | 2.07 Billion USD | 99.981% |
| Protagonist Therapeutics, Inc. | 56.68 Million USD | 99.314% |
| Erasca, Inc. | -3.73 Million USD | 110.423% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 1478.553% |
| Protagenic Therapeutics, Inc. | -28.21 Thousand USD | 1478.553% |
| Vincerx Pharma, Inc. | -915 Thousand USD | 142.514% |
| Fresh Tracks Therapeutics, Inc. | 8 Million USD | 95.141% |
| Acrivon Therapeutics, Inc. Common Stock | -536 Thousand USD | 172.575% |
| Celldex Therapeutics, Inc. | -111.12 Million USD | 100.35% |
| Cogent Biosciences, Inc. | -3.58 Million USD | 110.842% |
| Adicet Bio, Inc. | -6.09 Million USD | 106.379% |
| Amicus Therapeutics, Inc. | 362.03 Million USD | 99.893% |
| Aditxt, Inc. | -111.66 Thousand USD | 448.379% |
| Adagene Inc. | 18.11 Million USD | 97.852% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Quantum-Si incorporated | 488 Thousand USD | 20.287% |
| Acurx Pharmaceuticals, Inc. | - USD | -Infinity% |
| Voyager Therapeutics, Inc. | 157.83 Million USD | 99.754% |
| Compugen Ltd. | 31.45 Million USD | 98.763% |
| Generation Bio Co. | -73.91 Million USD | 100.526% |
| Astria Therapeutics, Inc. | - USD | -Infinity% |
| Black Diamond Therapeutics, Inc. | -437 Thousand USD | 189.016% |
| Invivyd, Inc. | -2.02 Million USD | 119.181% |
| Relay Therapeutics, Inc. | -300.84 Million USD | 100.129% |
| Quoin Pharmaceuticals, Ltd. | -103.43 Thousand USD | 476.071% |
| Spero Therapeutics, Inc. | 96.36 Million USD | 99.596% |
| Artelo Biosciences, Inc. | - USD | -Infinity% |
| 2seventy bio, Inc. | 98.28 Million USD | 99.604% |
| Instil Bio, Inc. | -4.75 Million USD | 108.179% |
| Capricor Therapeutics, Inc. | 24.1 Million USD | 98.387% |
| Elevai Labs, Inc. Common Stock | 1.13 Million USD | 65.714% |
| GeoVax Labs, Inc. | -20.72 Million USD | 101.877% |
| Citius Pharmaceuticals, Inc. | -194.31 Thousand USD | 300.189% |
| Relmada Therapeutics, Inc. | - USD | -Infinity% |
| ALX Oncology Holdings Inc. | -836 Thousand USD | 146.531% |
| Vir Biotechnology, Inc. | 83.41 Million USD | 99.534% |
| Evaxion Biotech A/S | 73.11 Thousand USD | -432.06% |
| Ocular Therapeutix, Inc. | 53.16 Million USD | 99.268% |
| Verve Therapeutics, Inc. | -173.18 Million USD | 100.225% |
| Tyra Biosciences, Inc. | -353 Thousand USD | 210.198% |
| Cingulate Inc. | -582.91 Thousand USD | 166.733% |
| Galmed Pharmaceuticals Ltd. | -31 Thousand USD | 1354.839% |
| Unity Biotechnology, Inc. | -19.69 Million USD | 101.975% |
| Connect Biopharma Holdings Limited | -988 Thousand USD | 139.372% |
| Clearmind Medicine Inc. | -56.34 Thousand USD | 790.426% |
| Bolt Biotherapeutics, Inc. | -53.66 Million USD | 100.725% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| Viking Therapeutics, Inc. | -292 Thousand USD | 233.219% |
| Madrigal Pharmaceuticals, Inc. | -527 Thousand USD | 173.814% |
| ImmunityBio, Inc. | -17.89 Million USD | 102.174% |
| Korro Bio, Inc. | -3.63 Million USD | 110.716% |
| Kineta, Inc. | 5.43 Million USD | 92.84% |
| BioVie Inc. | -229.37 Thousand USD | 269.59% |
| Codexis, Inc. | 57.33 Million USD | 99.322% |
| Celularity Inc. | 6.75 Million USD | 94.241% |
| Aileron Therapeutics, Inc. | -119 Thousand USD | 426.891% |
| Crinetics Pharmaceuticals, Inc. | 4.01 Million USD | 90.307% |
| Virax Biolabs Group Limited | 50.59 Thousand USD | -668.927% |
| Cibus, Inc. | 1.42 Million USD | 72.644% |
| IN8bio, Inc. | -2.5 Million USD | 115.554% |
| Adverum Biotechnologies, Inc. | -2.04 Million USD | 119.031% |
| Avalo Therapeutics, Inc. | 640 Thousand USD | 39.219% |
| Ionis Pharmaceuticals, Inc. | 778.51 Million USD | 99.95% |
| Eyenovia, Inc. | - USD | -Infinity% |
| Puma Biotechnology, Inc. | 172.95 Million USD | 99.775% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| Elevation Oncology, Inc. | -39 Thousand USD | 1097.436% |
| Xilio Therapeutics, Inc. | -1.9 Million USD | 120.474% |
| Cardiff Oncology, Inc. | -32.36 Million USD | 101.202% |
| Enanta Pharmaceuticals, Inc. | 79.2 Million USD | 99.509% |
| Regulus Therapeutics Inc. | -21.15 Million USD | 101.839% |
| Moolec Science SA | -143.3 Thousand USD | 371.449% |
| Acumen Pharmaceuticals, Inc. | -42.31 Million USD | 100.919% |
| LAVA Therapeutics N.V. | 3.28 Million USD | 88.166% |
| Atea Pharmaceuticals, Inc. | -70.09 Million USD | 100.555% |
| Compass Therapeutics, Inc. | -1.89 Million USD | 120.582% |
| Greenwich LifeSciences, Inc. | -3612.00 USD | 10869.657% |
| TFF Pharmaceuticals, Inc. | 231.39 Thousand USD | -68.114% |
| Humacyte, Inc. | -76.55 Million USD | 100.508% |
| PMV Pharmaceuticals, Inc. | -1.25 Million USD | 130.947% |
| Avenue Therapeutics, Inc. | - USD | -Infinity% |
| Genelux Corporation | -848 Thousand USD | 145.873% |
| Trevi Therapeutics, Inc. | -123 Thousand USD | 416.26% |
| Notable Labs, Ltd. | 113 Thousand USD | -244.248% |
| Immunovant, Inc. | -231 Thousand USD | 268.398% |
| Quantum-Si incorporated | 488 Thousand USD | 20.287% |
| DiaMedica Therapeutics Inc. | -30 Thousand USD | 1396.667% |
| Vera Therapeutics, Inc. | 1.86 Million USD | 79.108% |
| Acasti Pharma Inc. | -11 Thousand USD | 3636.364% |
| MiNK Therapeutics, Inc. | -204.61 Thousand USD | 290.111% |
| Soleno Therapeutics, Inc. | -1.95 Million USD | 119.867% |
| PepGen Inc. | -1.18 Million USD | 132.855% |
| Nuvectis Pharma, Inc. | -22.89 Million USD | 101.699% |
| BriaCell Therapeutics Corp. | -82.58 Thousand USD | 571.041% |
| Immuneering Corporation | -764.13 Thousand USD | 150.907% |
| Lixte Biotechnology Holdings, Inc. | - USD | -Infinity% |
| Belite Bio, Inc | -399 Thousand USD | 197.494% |
| XOMA Corporation | 3.86 Million USD | 89.925% |
| ARS Pharmaceuticals, Inc. | -20.03 Million USD | 101.942% |
| Bionomics Limited | -434.44 Thousand USD | 189.539% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 136.22% |
| uniQure N.V. | 2.21 Million USD | 82.438% |
| Estrella Immunopharma, Inc. | - USD | -Infinity% |
| Poseida Therapeutics, Inc. | -92.06 Million USD | 100.423% |
| Forte Biosciences, Inc. | -9000.00 USD | 4422.222% |
| Anebulo Pharmaceuticals, Inc. | - USD | -Infinity% |
| Enlivex Therapeutics Ltd. | -835 Thousand USD | 146.587% |
| Conduit Pharmaceuticals Inc. | - USD | -Infinity% |
| SeaStar Medical Holding Corporation | - USD | -Infinity% |
| FibroBiologics, Inc. Common Stock | -437 Thousand USD | 189.016% |
| Altimmune, Inc. | -65.37 Million USD | 100.595% |
| LENZ Therapeutics, Inc. | -2.4 Million USD | 116.161% |
| Alpha Tau Medical Ltd. | -1.07 Million USD | 136.22% |
| Peak Bio, Inc. | 367.76 Thousand USD | -5.773% |
| Zevra Therapeutics, Inc. | 24.51 Million USD | 98.413% |
| Benitec Biopharma Inc. | 108 Thousand USD | -260.185% |
| Spyre Therapeutics, Inc. | -78 Thousand USD | 598.718% |
| NKGen Biotech, Inc. Common Stock | -1.2 Million USD | 132.336% |
| Zura Bio Limited | - USD | -Infinity% |
| PolyPid Ltd. | -1.82 Million USD | 121.35% |
| NKGen Biotech, Inc. Warrants | -1.2 Million USD | 132.336% |
| argenx SE | 1.1 Billion USD | 99.965% |
| Immunome, Inc. | -8.9 Million USD | 104.367% |
| Verona Pharma plc | -679.62 Thousand USD | 157.238% |
| enGene Holdings Inc. Warrants | -175 Thousand USD | 322.286% |
| Shattuck Labs, Inc. | -2.38 Million USD | 116.31% |
| CervoMed Inc. | -1.29 Million USD | 130.07% |
| Plus Therapeutics, Inc. | -4.77 Million USD | 108.143% |
| Dianthus Therapeutics, Inc. | 2.47 Million USD | 84.257% |
| Moolec Science SA | -143.3 Thousand USD | 371.449% |
| Enveric Biosciences, Inc. | -408.03 Thousand USD | 195.336% |
| Design Therapeutics, Inc. | -537 Thousand USD | 172.439% |
| Leap Therapeutics, Inc. | -427 Thousand USD | 191.101% |
| Seelos Therapeutics, Inc. | 2.14 Million USD | 81.873% |
| Achilles Therapeutics plc | -4.73 Million USD | 108.222% |
| CERo Therapeutics Holdings, Inc. | - USD | -Infinity% |
| CG Oncology, Inc. Common stock | -45.54 Million USD | 100.854% |
| Fractyl Health, Inc. Common Stock | 43 Thousand USD | -804.651% |
| Rani Therapeutics Holdings, Inc. | -822 Thousand USD | 147.324% |
| MoonLake Immunotherapeutics | -13.15 Thousand USD | 3056.376% |
| Tourmaline Bio, Inc. | -33 Thousand USD | 1278.788% |
| Beam Therapeutics Inc. | -59.67 Million USD | 100.652% |
| Mirum Pharmaceuticals, Inc. | 139.33 Million USD | 99.721% |
| AEON Biopharma, Inc. | - USD | -Infinity% |
| Aadi Bioscience, Inc. | 21.54 Million USD | 98.194% |
| Enliven Therapeutics, Inc. | -297 Thousand USD | 230.976% |
| Kiora Pharmaceuticals, Inc. | -4.02 Million USD | 109.66% |
| NeurAxis, Inc. | 2.15 Million USD | 81.963% |
| Iovance Biotherapeutics, Inc. | -9.56 Million USD | 104.066% |
| Lumos Pharma, Inc. | 2 Million USD | 80.618% |
| Opiant Pharmaceuticals, Inc. | 31.65 Million USD | 98.771% |
| Palisade Bio, Inc. | 246 Thousand USD | -58.13% |
| Nutriband Inc. | 862.1 Thousand USD | 54.878% |
| Taysha Gene Therapies, Inc. | 14.08 Million USD | 97.237% |
| Neurogene Inc. | -3.26 Million USD | 111.925% |
| Kintara Therapeutics, Inc. | -55 Thousand USD | 807.273% |
| CARGO Therapeutics, Inc. Common Stock | -3.69 Million USD | 110.536% |
| Athira Pharma, Inc. | -969 Thousand USD | 140.144% |
| HCW Biologics Inc. | -574.82 Thousand USD | 167.673% |
| XOMA Corporation | 3.86 Million USD | 89.925% |
| Nektar Therapeutics | 53.47 Million USD | 99.273% |
| Arvinas, Inc. | 71.8 Million USD | 99.458% |
| Tevogen Bio Holdings Inc. | - USD | -Infinity% |
| Merus N.V. | -83.46 Million USD | 100.466% |
| Omega Therapeutics, Inc. | -62.77 Million USD | 100.62% |
| Quince Therapeutics, Inc. | -322 Thousand USD | 220.807% |
| Rezolute, Inc. | -36 Thousand USD | 1180.556% |
| Clene Inc. | 533 Thousand USD | 27.017% |
| Indaptus Therapeutics, Inc. | -1284.00 USD | 30395.95% |
| BeyondSpring Inc. | 1.75 Million USD | 77.784% |
| Synlogic, Inc. | -1.92 Million USD | 120.218% |
| Allarity Therapeutics, Inc. | -37 Thousand USD | 1151.351% |
| Phio Pharmaceuticals Corp. | -6.33 Million USD | 106.143% |
| Peak Bio, Inc. | 367.76 Thousand USD | -5.773% |
| Werewolf Therapeutics, Inc. | -18.96 Million USD | 102.051% |
| Krystal Biotech, Inc. | 47.6 Million USD | 99.183% |
| Karyopharm Therapeutics Inc. | 141.09 Million USD | 99.724% |
| SpringWorks Therapeutics, Inc. | 5.02 Million USD | 92.259% |
| Lipella Pharmaceuticals Inc. | -2.58 Million USD | 115.024% |
| MannKind Corporation | 136.19 Million USD | 99.714% |
| Ikena Oncology, Inc. | -50.49 Million USD | 100.77% |
| Cyclerion Therapeutics, Inc. | - USD | -Infinity% |
| Gyre Therapeutics, Inc. | 108.81 Million USD | 99.643% |
| Gossamer Bio, Inc. | -4.38 Million USD | 108.871% |
| CohBar, Inc. | - USD | -Infinity% |
| Cognition Therapeutics, Inc. | -252 Thousand USD | 254.365% |
| NRx Pharmaceuticals, Inc. | -5000.00 USD | 7880.0% |
| Legend Biotech Corporation | 140.92 Million USD | 99.724% |
| Mural Oncology plc | -2.56 Million USD | 115.154% |
| Disc Medicine, Inc. | -100 Thousand USD | 489.0% |
| Champions Oncology, Inc. | 20.75 Million USD | 98.126% |
| REGENXBIO Inc. | 53.02 Million USD | 99.266% |
| Ensysce Biosciences, Inc. | -5.35 Million USD | 107.262% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Cellectar Biosciences, Inc. | -192.37 Thousand USD | 302.209% |
| Edgewise Therapeutics, Inc. | -1.73 Million USD | 122.46% |
| Vaxart, Inc. | -60.76 Million USD | 100.64% |
| PharmaCyte Biotech, Inc. | - USD | -Infinity% |
| Aldeyra Therapeutics, Inc. | -262.78 Thousand USD | 248.033% |
| Cellectis S.A. | 18 Thousand USD | -2061.111% |
| Longeveron Inc. | 221 Thousand USD | -76.018% |
| Repare Therapeutics Inc. | -80.07 Million USD | 100.486% |
| Sarepta Therapeutics, Inc. | 1.09 Billion USD | 99.964% |
| Inozyme Pharma, Inc. | -1.29 Million USD | 130.062% |
| Revolution Medicines, Inc. | -399.66 Million USD | 100.097% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| Third Harmonic Bio, Inc. | -35 Thousand USD | 1211.429% |
| ArriVent BioPharma, Inc. Common Stock | - USD | -Infinity% |
| AN2 Therapeutics, Inc. | - USD | -Infinity% |
| Anixa Biosciences, Inc. | 49 Thousand USD | -693.878% |
| Vertex Pharmaceuticals Incorporated | 8.6 Billion USD | 99.995% |
| Denali Therapeutics Inc. | -93.34 Million USD | 100.417% |
| Revelation Biosciences, Inc. | -25.04 Thousand USD | 1652.956% |
| Veru Inc. | 7.56 Million USD | 94.859% |
| Corvus Pharmaceuticals, Inc. | -151 Thousand USD | 357.616% |
| Cingulate Inc. | -582.91 Thousand USD | 166.733% |
| Passage Bio, Inc. | -3.72 Million USD | 110.454% |
| Context Therapeutics Inc. | -12.04 Thousand USD | 3329.824% |
| Exicure, Inc. | -1.42 Million USD | 127.337% |
| Day One Biopharmaceuticals, Inc. | -383 Thousand USD | 201.567% |
| Oramed Pharmaceuticals Inc. | 2.7 Million USD | 85.609% |
| Scinai Immunotherapeutics Ltd. | -512.67 Thousand USD | 175.877% |
| Nuvalent, Inc. | - USD | -Infinity% |
| ABVC BioPharma, Inc. | -149.6 Thousand USD | 360.015% |
| Carisma Therapeutics, Inc. | -59.2 Million USD | 100.657% |
| Unicycive Therapeutics, Inc. | 391 Thousand USD | 0.512% |
| OmniAb, Inc. | 14.66 Million USD | 97.348% |
| Anew Medical, Inc. | - USD | -Infinity% |
| Fennec Pharmaceuticals Inc. | 19.99 Million USD | 98.054% |
| Lipocine Inc. | -2.85 Million USD | 113.645% |
| Lexeo Therapeutics, Inc. Common Stock | -1.84 Million USD | 121.107% |
| Nautilus Biotechnology, Inc. | -5.7 Million USD | 106.819% |
| SAB Biotherapeutics, Inc. | -1.5 Million USD | 125.825% |
| G1 Therapeutics, Inc. | 75.31 Million USD | 99.484% |
| Bellerophon Therapeutics, Inc. | -65 Thousand USD | 698.462% |
| Sage Therapeutics, Inc. | 84.29 Million USD | 99.539% |
| Ocugen, Inc. | -33.53 Million USD | 101.16% |
| Mind Medicine (MindMed) Inc. | -3.16 Million USD | 112.302% |
| Q32 Bio Inc. | 578 Thousand USD | 32.699% |
| Brainstorm Cell Therapeutics Inc. | -265 Thousand USD | 246.792% |
| Alumis Inc. Common Stock | -1.28 Million USD | 130.296% |
| Equillium, Inc. | 35.95 Million USD | 98.918% |
| Kyverna Therapeutics, Inc. | -1.7 Million USD | 122.789% |
| Coya Therapeutics, Inc. | 500.67 Thousand USD | 22.306% |
| CNS Pharmaceuticals, Inc. | -4134.00 USD | 9509.773% |
| Dominari Holdings Inc. | 2.03 Million USD | 80.922% |
| Edesa Biotech, Inc. | -183.47 Thousand USD | 312.023% |
| vTv Therapeutics Inc. | -13.59 Million USD | 102.861% |
| Bio-Techne Corporation | 773.07 Million USD | 99.95% |
| Agios Pharmaceuticals, Inc. | 17.31 Million USD | 97.754% |
| Harmony Biosciences Holdings, Inc. | 460.78 Million USD | 99.916% |
| Prelude Therapeutics Incorporated | -1.16 Million USD | 133.276% |
| Candel Therapeutics, Inc. | -23.98 Million USD | 101.622% |
| iTeos Therapeutics, Inc. | 11.69 Million USD | 96.674% |
| Nkarta, Inc. | -5.86 Million USD | 106.628% |
| BioCardia, Inc. | -7.24 Million USD | 105.366% |
| Iterum Therapeutics plc | -1.75 Million USD | 122.229% |